Fortress Biotech, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Fortress Biotech, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales grew in 2 of the last 3 years; profit grew in 3 of 3. Steadier than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
$37For every $100 of sales, $37 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $24 from others' credit three years earlier.
More money tied up than 77% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 3/3Sales grew in 2 of the last 3 years; profit grew in 3 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 16%
Sales fell 16% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-16% / -37%In 3 years sales changed by -16% while total assets changed by -37%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-30.9×Operating cash was negative last year, while some debt falls due within a year.
Lower than 64% of Healthcare companies in United States.
Cash Cushion Ratio
+8%Cash, after subtracting all debt, equals 8% of its market value (net cash).
Lower than 53% of Healthcare companies in United States.
Tangible Assets Ratio
85%Of every $100 the company owns, $85 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 56% of Healthcare companies in United States.
Tangible Net Worth Ratio
45%Of every $100 of net worth, $45 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 55% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Fortress Biotech, Inc. owes $0.35 for every $1 it owns. Fortress Biotech, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
0.7Investors pay $0.7 for every $1 of Fortress Biotech, Inc.'s yearly profit, lower than 93% of Healthcare companies in United States.
P/B ratio
0.40The share price is 0.40 times Fortress Biotech, Inc.'s book value per share, lower than 93% of Healthcare companies in United States.
Market cap
$66 MThe total market value of all of Fortress Biotech, Inc.'s shares at today's price (share price × number of shares), smaller than 71% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$164 MWhat Fortress Biotech, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$4.92Net worth divided by the number of shares. The share price of $1.99 is 0.4 times this, which is the P/B above.
Return on equity (ROE)
116.0%Fortress Biotech, Inc. earned 116.0% on its shareholders' money over the last year, higher than almost all Healthcare companies in United States.
Owes vs Owns
0.35×Fortress Biotech, Inc. owes $0.35 for every $1 it owns (low), lower than 55% of Healthcare companies in United States.
Dividend yield
NoneFortress Biotech, Inc. does not currently pay a dividend.
Revenue growth
+10%Revenue rose 10% in the year to Dec 2025, and shrank 6% a year on average over 3 years.
Profit growth
Back to profitFortress Biotech, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Profit margin
10.8%Fortress Biotech, Inc. keeps $11 of every $100 of revenue as net profit.
Cash quality
-9.7×Cash from Fortress Biotech, Inc.'s business was -9.7× its reported profit in the year to Dec 2025 — the business used cash even though it reported a profit.
Interest cover
Not coveredFortress Biotech, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashFortress Biotech, Inc. held $5 M more cash than debt (net cash) at Dec 2025.
Questions
What is Fortress Biotech, Inc.'s P/E ratio?
Investors pay $0.7 for every $1 of Fortress Biotech, Inc.'s yearly profit, lower than 93% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Fortress Biotech, Inc.: $66 M ÷ $164 M (30 Jun 2026) = 0.4.
What is Fortress Biotech, Inc.'s return on equity?
Fortress Biotech, Inc. earned 116.0% on its shareholders' money over the last year, higher than almost all Healthcare companies in United States.
How much does Fortress Biotech, Inc. owe compared with what it owns?
Fortress Biotech, Inc. owes $0.35 for every $1 it owns (low), lower than 55% of Healthcare companies in United States.
Does Fortress Biotech, Inc. pay a dividend?
No. Fortress Biotech, Inc. does not currently pay a dividend.
Is Fortress Biotech, Inc.'s revenue growing?
Revenue rose 10% in the year to Dec 2025, and shrank 6% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.